Cardinal Health (NYSE: CAH) has announced two definitive agreements totalling approximately $360 million in cash to expand its at-Home Solutions division. The company is acquiring the Diabetes Health business of AdaptHealth Corp.
MoreARS Pharmaceuticals (Nasdaq: SPRY) has announced a new collaboration with former NFL quarterback and 2026 Hall of Fame inductee Drew Brees to raise awareness about severe allergic reactions. The campaign centres on
MoreGSK plc has secured its first-ever approved medicine in lung cancer after the US FDA granted approval to Jideytro (zidesamtinib) for adult patients with previously treated ROS1-positive non-small cell lung cancer. The
MoreHealthcare’s long-promised overhaul of prior authorisation remains a work in progress, with frontline physicians reporting limited improvements despite industry pledges and new federal requirements. A new American Medical Association survey found that
MorePresident Donald Trump has announced a phased tariff plan targeting generic drugs imported into the United States, beginning with a zero-tariff window starting August 1. Under the plan, generic drug imports will
MoreAlembic Pharmaceuticals has received a formal warning letter from the U.S. Food and Drug Administration targeting its bioequivalence research facility in Vadodara, India. The warning letter, dated July 10, 2026, follows an
MoreDoceree has unveiled Semmelweis, a proprietary artificial intelligence reasoning and orchestration model built exclusively for pharmaceutical commercialisation and marketing. The model serves as the intelligence layer powering Daily Command, Doceree’s newly launched
MoreSanofi has unveiled a revised executive lineup set to take effect on 1 September, as newly installed CEO Belén Garijo moves to reshape leadership across the organisation. Garijo, a former CEO of
MoreAmgen has agreed to a $74 million settlement to resolve a class action lawsuit alleging the biotechnology giant withheld critical tax liability information from investors for far too long. The preliminary settlement
MoreNovo Nordisk (NVO) Sues Eli Lilly (LLY) Over Allegedly Misleading Zepbound And Mounjaro Ad Campaigns
Novo Nordisk has filed a federal lawsuit against Eli Lilly and Company and Lilly USA, LLC over national advertising campaigns for two of its flagship weight-loss drugs. The suit was filed in
More
